^
    almost3years
    Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. (PubMed, Clin Cancer Res)
    These findings demonstrate that MSLN is a viable target for CAR T therapy in AML and that inhibiting MSLN shedding is a promising approach to improve CAR T efficacy.
    Journal • CAR T-Cell Therapy
    |
    MSLN (Mesothelin) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • ADAM17 (ADAM Metallopeptidase Domain 17)
    |
    MSLN positive
    |
    SS1(dsFv)-PE38
    over3years
    Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. (PubMed, Cancer)
    The MTD for single-agent LMB-100 was found to be 140 µg/kg given on a schedule of every other day for 3 doses every 3 weeks. Although less immunogenic than the first-generation antimesothelin immunotoxin SS1P, the majority of patients developed antidrug antibodies after 2 cycles, indicating that LMB-100 has limited antitumor efficacy as a single agent. Phase 2 studies of LMB-100 plus pembrolizumab currently are ongoing for patients with mesothelioma and lung cancer.
    Clinical • P1 data • Journal • PD(L)-1 Biomarker
    |
    MSLN (Mesothelin)
    |
    Keytruda (pembrolizumab) • LMB-100 • SS1(dsFv)-PE38
    almost4years
    Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. (PubMed, Biomolecules)
    This has led to multiple clinical trials, testing the safety and efficacy of the clinical leads SS1P and LMB-100. This review summarizes existing pre-clinical and clinical data on MSLN-targeted iTox's. In addition, we address the potential future directions of research to enhance the activity of these anti-tumor agents.
    Review • Journal
    |
    MSLN (Mesothelin)
    |
    LMB-100 • SS1(dsFv)-PE38